Investing.com - Financial Markets Worldwide
📈 Fed's first cut since 2020: Time to buy the dip? See Tech-focused stock picksUnlock AI Picks

Bristol-Myers' Opdivo extends survival in late-stage lung study in Chinese population

Published 04/13/2018, 05:00 PM
© Reuters. Bristol-Myers' Opdivo extends survival in late-stage lung study in Chinese population
BMY
-
  • Results a Phase 3 clinical trial, CheckMate-078, assessing Bristol-Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) compared to the chemo agent docetaxel in a predominantly Chinese population with previously treated advanced non-small cell lung cancer (NSCLC) showed a statistically significant improvement in overall survival (OS). The data will be presented on Monday, April 16, at the American Association for Cancer Research Annual Meeting in Chicago.
  • Patients receiving Opdivo experienced a reduction of 32% (hazard ratio = 0.68) in the relative risk of disease progression or death (p=0.0006). The OS benefit was observed regardless of PD -L1 expression or tumor histology.
  • The secondary endpoints of objective response rate (ORR) (17.4% vs. 4.0%) and median duration of response (mDOR) (not reached vs. 5.3 months) also showed the durability of Opdivo treatment compared to docetaxel.
  • The company's marketing application seeking approval for Opdivo in previously treated NSCLC is currently under CFDA review.
  • Now read: Biotechs, Whipsawed By Volatility, Still Remain Well-Positioned


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.